Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.22
GSK's Cash to Debt is ranked higher than
50% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. GSK: 0.22 )
GSK' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.22

Equity to Asset 0.13
GSK's Equity to Asset is ranked lower than
55% of the 757 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. GSK: 0.13 )
GSK' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.4
Current: 0.13

0.05
0.4
Interest Coverage 9.68
GSK's Interest Coverage is ranked higher than
55% of the 491 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 97.33 vs. GSK: 9.68 )
GSK' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 9.68

0.81
28.06
F-Score: 6
Z-Score: 2.16
M-Score: -2.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 22.54
GSK's Operating margin (%) is ranked higher than
93% of the 787 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.15 vs. GSK: 22.54 )
GSK' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 22.54

1.68
36.94
Net-margin (%) 17.63
GSK's Net-margin (%) is ranked higher than
91% of the 787 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.39 vs. GSK: 17.63 )
GSK' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 17.63

5.76
23.94
ROE (%) 68.04
GSK's ROE (%) is ranked higher than
99% of the 796 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.47 vs. GSK: 68.04 )
GSK' s 10-Year ROE (%) Range
Min: 17.3   Max: 267.32
Current: 68.04

17.3
267.32
ROA (%) 10.35
GSK's ROA (%) is ranked higher than
92% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. GSK: 10.35 )
GSK' s 10-Year ROA (%) Range
Min: 3.84   Max: 28.25
Current: 10.35

3.84
28.25
ROC (Joel Greenblatt) (%) 58.14
GSK's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.76 vs. GSK: 58.14 )
GSK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.44   Max: 150.31
Current: 58.14

5.44
150.31
Revenue Growth (%) -0.90
GSK's Revenue Growth (%) is ranked higher than
60% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. GSK: -0.90 )
GSK' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 91
Current: -0.9

-1.5
91
EBITDA Growth (%) 17.30
GSK's EBITDA Growth (%) is ranked higher than
82% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. GSK: 17.30 )
GSK' s 10-Year EBITDA Growth (%) Range
Min: -11.8   Max: 85.9
Current: 17.3

-11.8
85.9
EPS Growth (%) 51.40
GSK's EPS Growth (%) is ranked higher than
95% of the 627 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. GSK: 51.40 )
GSK' s 10-Year EPS Growth (%) Range
Min: -30.2   Max: 93.9
Current: 51.4

-30.2
93.9
» GSK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

GSK Guru Trades in Q3 2013

John Rogers 136,344 sh (+246.35%)
Jim Simons 3,891,300 sh (+186.65%)
Diamond Hill Capital 11,561 sh (+20.92%)
Murray Stahl 23,723 sh (+4.63%)
Manning & Napier Advisors, Inc 400,161 sh (+1.25%)
NWQ Managers 211,800 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
John Hussman 23,500 sh (unchged)
Tweedy Browne 151,030 sh (-0.04%)
Jeff Auxier 112,720 sh (-0.13%)
Ken Fisher 11,119,081 sh (-0.26%)
PRIMECAP Management 10,078,655 sh (-0.47%)
Dodge & Cox 61,290,600 sh (-1.04%)
Charles Brandes 1,896,714 sh (-1.82%)
Vanguard Health Care Fund 1,438,781 sh (-10.7%)
Steven Cohen 8,963 sh (-30%)
Warren Buffett 345,819 sh (-76.57%)
» More
Q4 2013

GSK Guru Trades in Q4 2013

Francis Chou 18,000 sh (New)
Joel Greenblatt 83,452 sh (New)
John Hussman 423,500 sh (+1702.13%)
John Rogers 421,201 sh (+208.93%)
Jim Simons 6,425,000 sh (+65.11%)
Charles Brandes 2,145,461 sh (+13.11%)
Ken Fisher 11,126,274 sh (+0.06%)
Diamond Hill Capital 11,561 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
Murray Stahl 23,723 sh (unchged)
Warren Buffett Sold Out
Steven Cohen Sold Out
Jeff Auxier 112,170 sh (-0.49%)
Tweedy Browne 150,184 sh (-0.56%)
PRIMECAP Management 9,998,877 sh (-0.79%)
NWQ Managers 209,325 sh (-1.17%)
Dodge & Cox 60,479,650 sh (-1.32%)
Manning & Napier Advisors, Inc 383,698 sh (-4.11%)
Vanguard Health Care Fund 644,881 sh (-55.18%)
» More
Q1 2014

GSK Guru Trades in Q1 2014

Louis Moore Bacon 75,000 sh (New)
Steven Cohen 5,921 sh (New)
HOTCHKIS & WILEY 36,773 sh (New)
Bill Frels 4,496 sh (New)
Diamond Hill Capital 190,984 sh (+1551.97%)
John Rogers 662,150 sh (+57.21%)
Jim Simons 7,009,800 sh (+9.1%)
Charles Brandes 2,164,241 sh (+0.88%)
Ken Fisher 11,214,364 sh (+0.79%)
Murray Stahl 23,792 sh (+0.29%)
Francis Chou 18,000 sh (unchged)
Joel Greenblatt 83,452 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
Vanguard Health Care Fund Sold Out
Dodge & Cox 60,386,550 sh (-0.15%)
Jeff Auxier 109,170 sh (-2.67%)
Tweedy Browne 142,598 sh (-5.05%)
PRIMECAP Management 9,177,877 sh (-8.21%)
Manning & Napier Advisors, Inc 329,053 sh (-14.24%)
John Hussman 323,500 sh (-23.61%)
NWQ Managers 148,800 sh (-28.91%)
» More
Q2 2014

GSK Guru Trades in Q2 2014

Pioneer Investments 93,226 sh (New)
James Barrow 270,900 sh (New)
HOTCHKIS & WILEY 4,949,118 sh (+13358.6%)
John Rogers 988,772 sh (+49.33%)
Jim Simons 8,869,400 sh (+26.53%)
Charles Brandes 2,500,048 sh (+15.52%)
Ken Fisher 11,365,903 sh (+1.35%)
Murray Stahl 23,992 sh (+0.84%)
Manning & Napier Advisors, Inc 331,544 sh (+0.76%)
Joel Greenblatt 83,528 sh (+0.09%)
NWQ Managers 148,850 sh (+0.03%)
Francis Chou 18,000 sh (unchged)
John Hussman 323,500 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
Louis Moore Bacon Sold Out
Dodge & Cox 60,226,050 sh (-0.27%)
Tweedy Browne 142,118 sh (-0.34%)
Jeff Auxier 108,620 sh (-0.5%)
Diamond Hill Capital 189,641 sh (-0.7%)
Bill Frels 3,846 sh (-14.46%)
PRIMECAP Management 5,156,449 sh (-43.82%)
» More
» Details

Insider Trades

Latest Guru Trades with GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2014-06-30 Add 13358.6%0.93%$51.55 - $56.39 $ 45.79-16%4949118
PRIMECAP Management 2014-06-30 Reduce -43.82%0.25%$51.55 - $56.39 $ 45.79-16%5156449
John Rogers 2014-06-30 Add 49.33%0.21%$51.55 - $56.39 $ 45.79-16%988772
Charles Brandes 2014-06-30 Add 15.52%0.21%$51.55 - $56.39 $ 45.79-16%2500048
James Barrow 2014-06-30 New Buy0.02%$51.55 - $56.39 $ 45.79-16%270900
John Hussman 2014-03-31 Reduce -23.61%0.38%$50.9 - $56.66 $ 45.79-15%323500
John Rogers 2014-03-31 Add 57.21%0.16%$50.9 - $56.66 $ 45.79-15%662150
Vanguard Health Care Fund 2014-03-31 Sold Out 0.11%$50.9 - $56.66 $ 45.79-15%0
NWQ Managers 2014-03-31 Reduce -28.91%0.03%$50.9 - $56.66 $ 45.79-15%148800
HOTCHKIS & WILEY 2014-03-31 New Buy0.01%$50.9 - $56.66 $ 45.79-15%36773
John Hussman 2013-12-31 Add 1702.13%1.51%$49.31 - $53.68 $ 45.79-12%423500
John Rogers 2013-12-31 Add 208.93%0.19%$49.31 - $53.68 $ 45.79-12%421201
Charles Brandes 2013-12-31 Add 13.11%0.16%$49.31 - $53.68 $ 45.79-12%2145461
Vanguard Health Care Fund 2013-12-31 Reduce -55.18%0.14%$49.31 - $53.68 $ 45.79-12%644881
Joel Greenblatt 2013-12-31 New Buy0.11%$49.31 - $53.68 $ 45.79-12%83452
Warren Buffett 2013-12-31 Sold Out 0.02%$49.31 - $53.68 $ 45.79-12%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on GlaxoSmithKline PLC

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Oct 17, 2014

We eliminated our position in GlaxoSmithKline PLC (GSK) due to concerns that the company will not be able to preserve the recent level of revenue or profitability generated by its respiratory franchise. Despite its development of high efficacy next generation respiratory drugs that have come to market in advance of Advair losing patent protection, the company is facing extreme pricing pressure from health care payors. Diversified machinery manufacturer Dover Corp. was eliminated as the stock price approached our estimate of intrinsic value.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Jun 26, 2014

Global pharmaceutical company GlaxoSmithKline PLC (GSK) has several attractive franchises and pipeline drug candidates that have the potential to add significant value.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

Diamond Hill Capital Comments on GlaxoSmithKline PLC
We eliminated our position in GlaxoSmithKline PLC (GSK) due to concerns that the company will not be able to preserve the recent level of revenue or profitability generated by its respiratory franchise. Despite its development of high efficacy next generation respiratory drugs that have come to market in advance of Advair losing patent protection, the company is facing extreme pricing pressure from health care payors. Diversified machinery manufacturer Dover Corp. was eliminated as the stock price approached our estimate of intrinsic value. Read more...
Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG
According to GuruFocus list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...
A Look at the Week's Top Dividend Growers
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
Diamond Hill Capital Comments on GlaxoSmithKline PLC
Global pharmaceutical company GlaxoSmithKline PLC (GSK) has several attractive franchises and pipeline drug candidates that have the potential to add significant value. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 16.50
GSK's P/E(ttm) is ranked higher than
93% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.30 vs. GSK: 16.50 )
GSK' s 10-Year P/E(ttm) Range
Min: 10.16   Max: 40.41
Current: 16.5

10.16
40.41
P/B 13.49
GSK's P/B is ranked lower than
62% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. GSK: 13.49 )
GSK' s 10-Year P/B Range
Min: 5.48   Max: 14.06
Current: 13.49

5.48
14.06
P/S 2.91
GSK's P/S is ranked higher than
73% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. GSK: 2.91 )
GSK' s 10-Year P/S Range
Min: 1.94   Max: 4.9
Current: 2.91

1.94
4.9
PFCF 19.67
GSK's PFCF is ranked higher than
92% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GSK: 19.67 )
GSK' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 19.67

8.21
41.33
EV-to-EBIT 15.58
GSK's EV-to-EBIT is ranked higher than
89% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.86 vs. GSK: 15.58 )
GSK' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 240.2
Current: 15.58

7.7
240.2
PEG 6.42
GSK's PEG is ranked higher than
84% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GSK: 6.42 )
GSK' s 10-Year PEG Range
Min: 0.24   Max: 547.67
Current: 6.42

0.24
547.67
Shiller P/E 16.18
GSK's Shiller P/E is ranked higher than
94% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 96.41 vs. GSK: 16.18 )
GSK' s 10-Year Shiller P/E Range
Min: 10.82   Max: 21.15
Current: 16.18

10.82
21.15
Current Ratio 0.97
GSK's Current Ratio is ranked lower than
51% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. GSK: 0.97 )
GSK' s 10-Year Current Ratio Range
Min: 0.97   Max: 1.78
Current: 0.97

0.97
1.78
Quick Ratio 0.69
GSK's Quick Ratio is ranked lower than
51% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. GSK: 0.69 )
GSK' s 10-Year Quick Ratio Range
Min: 0.68   Max: 1.42
Current: 0.69

0.68
1.42

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.80
GSK's Dividend Yield is ranked higher than
99% of the 493 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. GSK: 5.80 )
GSK' s 10-Year Dividend Yield Range
Min: 2.72   Max: 5.91
Current: 5.8

2.72
5.91
Dividend Payout 0.93
GSK's Dividend Payout is ranked higher than
99% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. GSK: 0.93 )
GSK' s 10-Year Dividend Payout Range
Min: 0.38   Max: 4.69
Current: 0.93

0.38
4.69
Dividend growth (3y) 6.40
GSK's Dividend growth (3y) is ranked higher than
82% of the 360 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. GSK: 6.40 )
GSK' s 10-Year Dividend growth (3y) Range
Min: -12.6   Max: 20.8
Current: 6.4

-12.6
20.8
Yield on cost (5-Year) 7.95
GSK's Yield on cost (5-Year) is ranked higher than
97% of the 501 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.41 vs. GSK: 7.95 )
GSK' s 10-Year Yield on cost (5-Year) Range
Min: 3.73   Max: 8.1
Current: 7.95

3.73
8.1
Share Buyback Rate 1.40
GSK's Share Buyback Rate is ranked higher than
90% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.20 vs. GSK: 1.40 )
GSK' s 10-Year Share Buyback Rate Range
Min: 51.8   Max: -20
Current: 1.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.44
GSK's Price/DCF (Projected) is ranked higher than
61% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.00 vs. GSK: 1.44 )
GSK' s 10-Year Price/DCF (Projected) Range
Min: 0.82   Max: 4.16
Current: 1.44

0.82
4.16
Price/Median PS Value 1.00
GSK's Price/Median PS Value is ranked higher than
51% of the 837 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.25 vs. GSK: 1.00 )
GSK' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 2.58
Current: 1

0.69
2.58
Earnings Yield (Greenblatt) 6.40
GSK's Earnings Yield (Greenblatt) is ranked higher than
82% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. GSK: 6.40 )
GSK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12.9
Current: 6.4

0.4
12.9
Forward Rate of Return (Yacktman) 5.27
GSK's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. GSK: 5.27 )
GSK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 65.1
Current: 5.27

2.2
65.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GLAXF.USA, GS7A.Germany, GS7.Germany, GSK N.Mexico, GSK.Argentina
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals including HIV, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, vaccines and dermatologicals. The Company operates in two industry segments: Pharmaceuticals and Consumer Healthcare. The Company's pharmaceutical products include treatments for asthma, HIV/AIDS, malaria, depression, migraine, diabetes, heart failure, digestive conditions and cancer. The Company markets over 25 vaccines worldwide to prevent potentially life-threatening or crippling illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. The Company produces medicines that treat six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, it is developing new treatments for cancer. The Company's portfolio comprises three main categories: OTC medicines, Oral healthcare and Nutritional healthcare. OTC medicines- alli is the first licensed weight loss medicine to be available without a prescription, launched in the USA in 2007. Oral healthcare- Aquafresh, a range of toothpastes, toothbrushes and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene; Polident, PoliGrip and Corega, the denture care cleansers and adhesives; and Other brands include Odol, Macleans and Dr Best. Nutritional healthcare- Lucozade is a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. The Company has operations in USA, Europe, Asia Pacific, Japan and Canada.
» More Articles for NYSE:GSK

Headlines

Articles On GuruFocus.com
Tweedy Browne Global Value Fund's Top Picks for Q3 Oct 21 2014 
Diamond Hill Capital Comments on GlaxoSmithKline PLC Oct 17 2014 
Dodge & Cox’ Stock Fund Third Quarter 2014 Commentary Oct 16 2014 
Ebola: Is The Cure Out There? Oct 14 2014 
Guru Stocks at 52-Week Lows: GE, BHP, TOT, BP, GSK Oct 12 2014 
Guru Stocks at 52-Week Lows: BHP, GSK, UTX, SAP, TEF Sep 30 2014 
International Securities For A Diversified Income Portfolio Sep 23 2014 
Widely Held Guru Stocks Trading In Europe Sep 22 2014 
Guru Stocks at 52-Week Lows: BHP, GSK, EC, VALE, ABB Sep 21 2014 
Guru Stocks at 52-Week Lows: BHP, GSK, VOD, LYG, TEF Sep 16 2014 


More From Other Websites
Director/PDMR Shareholding Oct 24 2014
J&J and Glaxo Ready to Collaborate for Ebola Vaccine Work Oct 24 2014
Glaxo Gains on Q3 Earnings Beat and Restructuring Plans Oct 24 2014
Head of GSK Ebola Vaccine Research: "Can We Even Consider Doing A Trial?" Oct 23 2014
Drugmakers want indemnity Oct 23 2014
Director/PDMR Shareholding Oct 23 2014
[$$] GlaxoSmithKline Unveils Cost-Saving Plan, Considers IPO of HIV Business Oct 22 2014
Stocks Erase Gains to End Lower Oct 22 2014
Stocks Move Higher Again After Earnings Oct 22 2014
Glaxo Considers ViiV IPO to Capitalize on HIV-Drug Sales Oct 22 2014
GlaxoSmithKline plc Jumps After Beating City Expectations Oct 22 2014
GlaxoSmithKline moving forward with Ebola vaccine Oct 22 2014
Why GlaxoSmithKline (GSK) Stock Is Up Today Oct 22 2014
GSK CEO and CFO Interviewed on 2014 Q3 Results Oct 22 2014
Re Directorate Oct 22 2014
Glaxo Third-Quarter Profit Beat Estimates Oct 22 2014
Trading Ebola Oct 21 2014
Vaccines, Medical Oxygen, and Helping the Ebola Crisis Oct 21 2014
Glaxo Rising Star Connelly Under Pressure as Drugs Falter Oct 21 2014
Will GlaxoSmithKline (GSK) Earnings Suffer on China Probe? Oct 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK